SeaStar Medical Announces DSMB-Backed Continuation and Expanded Enrollment of Pivotal NEUTRALIZE-AKI Trial for Acute Kidney Injury Therapy
SeaStar Medical Holding Corporation has announced that the independent Data Safety Monitoring Review Board (DSMB) has recommended continuation of the NEUTRALIZE-AKI pivotal trial evaluating the Selective Cytopheretic Device $(SCD)$ therapy in adult patients with acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT). The DSMB reported no device-related safety concerns and identified a signal of potential clinical benefit in the treatment group across key study outcomes. To strengthen statistical power, the DSMB advised increasing total enrollment from 200 to 339 patients. As of the latest update, 137 patients have been enrolled, and study completion is projected near the end of 2026. Results from the trial have not yet been presented, as patient enrollment is ongoing.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seastar Medical Holding Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9534782-en) on September 24, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。